The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos…
Read More
Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration
Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…
Read More
Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read More
Bristol Myers Squibb and Oxford BioTherapeutics Forge Alliance to Pioneer Novel T-Cell Engager Therapies for Solid Tumors
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have announced a significant strategic alliance aimed at discovering and developing a…
Read MoreYOU MAY HAVE MISSED
